Research Topics
Species | Jennifer K LittonSummaryAffiliation: The University of Texas Country: USA Publications
| Collaborators
|
Detail Information
Publications
Breast cancer and fertilityJennifer K Litton
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Curr Treat Options Oncol 13:137-45. 2012..Further safety and outcomes studies are warranted for children...
Multifocal breast cancer in women < or =35 years oldJennifer K Litton
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 110:1445-50. 2007..The relation that multifocality at diagnosis had to survival in women < 35 years of age was evaluated...- Aromatase inhibitors and breast cancer preventionJennifer Keating Litton
The University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA
Expert Opin Pharmacother 13:325-31. 2012..We continue to await further follow-up on exemestane as well as other aromatase inhibitors in the prevention setting for women at high risk of developing breast cancer or with a history of ductal carcinoma in situ... - Earlier age of onset of BRCA mutation-related cancers in subsequent generationsJennifer K Litton
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer 118:321-5. 2012..In this study, the authors assessed age at diagnosis in 2 generations of families with known mutations to investigate for earlier onset in subsequent generations... 
Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutationJennifer K Litton
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cancer 115:1598-604. 2009..Women at a high risk for breast cancer are offered choices for screening or prophylactic surgeries. The aim of this study was to evaluate opinions regarding screening and surgical strategies in high-risk women...- Breast cancer diagnosis during pregnancyJennifer K Litton
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
Womens Health (Lond Engl) 5:243-9. 2009..In this article, the use of diagnostic imaging, procedures, surgery and chemotherapy are reviewed as well as prognosis and future pregnancies after the treatment for breast cancer... - Breast cancer and pregnancy: current concepts in diagnosis and treatmentJennifer K Litton
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Oncologist 15:1238-47. 2010..This review details the available data regarding the diagnosis and management of the pregnant breast cancer patient... - Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtypeRachel L Theriault
Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Clin Breast Cancer 11:325-31. 2011..This article evaluates the risk of recurrence for patients who have small node-negative breast cancer by age and tumor subtype... - Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapyAbigail S Caudle
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Hermann Pressler Drive, Unit 1484, Houston, TX 77030, USA
Breast Cancer Res 14:R83. 2012.... - Triple-negative breast cancer is not a contraindication for breast conservationFarrell C Adkins
Department of Surgical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
Ann Surg Oncol 18:3164-73. 2011..Triple-negative breast cancer (TNBC) is an aggressive subtype shown to have a high risk of locoregional recurrence (LRR). The purpose of this study was to determine the impact of operation type on LRR in TNBC patients... - Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body massHenry M Kuerer
Department of Surgical Oncology, DCIS Discovery Enterprise, Unit 1484, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX 77230 1402, USA
Breast Cancer Res Treat 133:1131-41. 2012..Furthermore, there was no significant difference in risk of recurrence between diabetic patients receiving metformin or not. In conclusion, higher BMI is not associated with adverse biologic features or prognosis in patients with DCIS... - Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapyRanjna Sharma
Department of Surgical Oncology, Plastic Surgery, Radiation Oncology, and Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Plast Reconstr Surg 127:1763-72. 2011.... - Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancerSoley Bayraktar
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer 118:1202-11. 2012..In the current study, the authors explored the association between metformin use and survival outcomes in patients with triple receptor-negative breast cancer (TNBC) who were receiving adjuvant chemotherapy... - Ten-year recurrence rates in young women with breast cancer by locoregional treatment approachBeth M Beadle
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 73:734-44. 2009..The goal of this study is to determine the impact of locoregional treatment strategy, breast-conserving therapy (BCT), mastectomy alone (M), or mastectomy with adjuvant radiation (MXRT), on LRR for patients 35 years or younger... - Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancersCatherine M Kelly
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Cancer 116:5161-7. 2010..The authors hypothesized that the test is ordered when clinicopathological variables yield equivocal risk estimates. The current study also showed how often the test clarifies clinically ambiguous risk status... - High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smallerAna M Gonzalez-Angulo
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
J Clin Oncol 27:5700-6. 2009..To evaluate the risk of recurrence in women diagnosed with T1a and T1b, node-negative, human epidermal growth factor receptor 2 (HER2) -positive breast cancer... - The impact of pregnancy on breast cancer outcomes in women<or=35 yearsBeth M Beadle
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 115:1174-84. 2009..The purpose of the current study was to compare locoregional recurrence (LRR), distant metastases (DM), and overall survival (OS) in young patients with PABC and non-PABC... - Clinical application of breast cancer risk assessment modelsKaylene Ready
The Univeristy of Texas MD Anderson Cancer Center, Houston, 77030, USA
Future Oncol 6:355-65. 2010..Their clinical applications are also outlined and clinical situations appropriate for each model are reviewed... - Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancerHuong T Le-Petross
Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Cancer 117:3900-7. 2011..In this study, the authors investigated the efficacy of alternating screening mammography and breast MRI every 6 months in women who had a genetically high risk of developing breast cancer... - Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancerAna M Gonzalez-Angulo
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Clin Cancer Res 17:1082-9. 2011..Survival was estimated by Kaplan-Meier method and compared with log-rank. Cox proportional hazards models were fit to determine the independent association of mutation status with outcome... - Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutationsSoley Bayraktar
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Breast Cancer Res Treat 130:145-53. 2011..Further studies need to evaluate whether different therapies will change the outcome in these subgroups of TNBC... - Early onset HER2-positive breast cancer is associated with germline TP53 mutationsAmal Melhem-Bertrandt
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 118:908-13. 2012..Germline TP53 mutations predispose to early onset breast cancer in women and are associated with Li-Fraumeni syndrome. Published data on the pathological characteristics of breast cancer among women with TP53 mutations is limited... - Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancerJennifer K Litton
Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
J Clin Oncol 26:4072-7. 2008..To understand the mechanism through which obesity in breast cancer patients is associated with poorer outcome, we evaluated body mass index (BMI) and response to neoadjuvant chemotherapy (NC) in women with operable breast cancer... - Sentinel lymph node dissection is technically feasible in older breast cancer patientsVicente Valero
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Clin Breast Cancer 10:477-82. 2010..This study was undertaken to compare identification rates in patients 70 years of age and older versus those younger than 70 years in a large cohort undergoing sentinel lymph node dissection (SLND)...